SABS
SAB Biotherapeutics, Inc.
Key Financials
Operating Income
$-48953363
↓ 14.1%
EPS (Diluted)
$-0.79
↑ 78.5%
Total Assets
$172.8M
↑ 291.0%
Net Income
$13.3M
↑ 138.9%
Cash & Equivalents
$10.5M
↑ 18.0%
Revenue
$0
↓ 100.0%
Total Liabilities
$21.3M
↑ 17.0%
Shareholders' Equity
$151.5M
↑ 483.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| 8-K | 5/4/2026 | View on SEC |
| SCHEDULE 13G | 5/1/2026 | View on SEC |
| DEF 14A | 4/30/2026 | View on SEC |
| 8-K | 4/22/2026 | View on SEC |
| S-8 | 3/31/2026 | View on SEC |
| 4 | 3/25/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SABS |
| Company Name | SAB Biotherapeutics, Inc. |
| CIK | 1833214 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 305-845-2813 |